# TREATMENT AND MAINTENANCE OF XEROTIC SKIN USING A ONCE DAILY LIPID REPLENISHING CLEANSER AND MOISTURIZER

#### C Sibley<sup>1</sup>, K Beleznay<sup>2</sup>, D Diao<sup>3</sup>, N Hawkins<sup>4</sup>, N Dayeh<sup>5</sup>

1. Victoria Park Ottawa – Laserderm, ON, Canada.

- 2. Humphrey Cosmetic Dermatology, Vancouver, BC, Canada.
- 3. Department of Dermatology and Skin Science, University of British Columbia, BC, Canada; Pacific Derm, Vancouver, BC, Canada.
- 4. Dermapure, Calgary, AB, Canada.
- 5. La Roche-Posay Laboratoire Dermatologique, L'Oreal Canada

## INTRODUCTION

Xerotic skin presents with dryness, scales, and flakes, which can lead to fissures, cracks, and may be associated with eczema. These signs and symptoms can negatively affect patients' quality of life. The purpose of this open-label, multicentre cohort study was to evaluate the improvement of mild-to-moderate xerosis following the use of a once-daily gentle cleanser and moisturizer, over a duration of 28 days.

### MATERIAL & METHODS


The study recruited subjects from 4 Canadian sites with a documented history of xerosis on the torso, arms, and/or legs. The subjects applied a routine of a cleanser and a moisturizer containing *Aqua Posae Filiformis*, microrésyl, shea butter and niacinamide once a day. Clinical assessments were performed at baseline and end of study (Day 28 +/- 5 days) using the physician-assessed Dry Skin Classification Scale (DSCS) and the Global Aesthetic Improvement Scale (GAIS). The primary study endpoint was the proportion of subjects having at least a one-grade improvement in skin dryness, based on the DSCS.

## RESULTS


In total, 48 subjects were enrolled, with 47 subjects 8 males and 40 females completing all study endpoints.



- Safety: No product-related adverse events were reported.
- Compliance: All subjects (100%) reported being entirely compliant with the once-daily application regimen.



- 51.06% (n = 24) of subjects demonstrating a multi-point decrease
- 40.43% (n = 19) of subjects demonstrating a single-point decrease



• At the end of the study, 95.74% (45/47) of subjects at least improved on the physician-assessed GAIS

#### DISCUSSION

All subjects (100%) reported being entirely compliant with the once-daily application regimen. No product-related adverse events were reported. In addition, 91.49% of subjects in the per-protocol population met the primary endpoint, including: 51.06% of subjects demonstrating a multi-point decrease and 40.43% of subjects demonstrating a multi-point decrease in skin dryness. At the end of the study, 95.74% of subjects at least "improved" based on the physician-assessed GAIS.

The once-daily regimen was very well tolerated in a cohort of subjects that are prone to skin irritation. The investigative cleanser and moisturizer significantly improved clinical signs of xerosis, including skin dryness.

